Astion Pharma 
Welcome,         Profile    Billing    Logout  
 2 Products   9 Diseases  2 Products   4 Trials   0 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
monooctanoin/ nicotinamide cream (ASF 1057) / Astion Pharma
2007-004649-14: Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial

Ongoing
3
150
Europe
ASF-1057-Cream 0.5%,
Astion Pharma A/S
Seborrhoeic dermatitis
 
 
2006-005637-37: Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% Nicotinamide combined with either 0%, 0.5% or 1.0% GMCY with the placebo cream.

Ongoing
2
100
Europe
ASF-1057 cream glycerylmonocaprylate 1.0% + nictotinamide 2%, ASF-1057 cream glycerylmonocaprylate 0.5% + nictotinamide 2%, ASF-1057 cream glycerylmonocaprylate 0% + nictotinamide 2%,
Astion Danmark A/S
Seborrhoeic Dermatitis.
 
 
salbutamol (ASF-1096) / Cipher, Astion Pharma
2007-004635-29: Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions

 
3
36
Europe
ASF-1096 Cream 0.25%, ASF-1096 Cream 0.5%, ASF-1096 Cream 1.0%,
Astion Pharma A/S
Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.
 
 
2006-001062-17: Efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with newly developed discoid lupus erythymatosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double blind proof of concept study.

 
2
20
Europe
ASF-1096 cream 0.5%,
Astion Danmark A/S
Male or female patients with a clinical diagnosis of either Discoid Lupus Erythmatosus or Systemic Lupus Erythmatosus and at least one newly developed, sharply demarcated DLE lesion.
 
07/07
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
monooctanoin/ nicotinamide cream (ASF 1057) / Astion Pharma
2007-004649-14: Safety of ASF 1057 cream 0.5% under long term use in the treatment of seborrhoeic dermatitis: A 12 month open label extension multi-centre phase III trial

Ongoing
3
150
Europe
ASF-1057-Cream 0.5%,
Astion Pharma A/S
Seborrhoeic dermatitis
 
 
2006-005637-37: Comparative, placebo controlled, double-blind efficacy and safety study in patients with seborrhoeic dermatitis comparing a topical cream containing 2% Nicotinamide combined with either 0%, 0.5% or 1.0% GMCY with the placebo cream.

Ongoing
2
100
Europe
ASF-1057 cream glycerylmonocaprylate 1.0% + nictotinamide 2%, ASF-1057 cream glycerylmonocaprylate 0.5% + nictotinamide 2%, ASF-1057 cream glycerylmonocaprylate 0% + nictotinamide 2%,
Astion Danmark A/S
Seborrhoeic Dermatitis.
 
 
salbutamol (ASF-1096) / Cipher, Astion Pharma
2007-004635-29: Randomised, placebo controlled, international multi-centre, double blind, dose confirmation study testing the safety and efficacy of ASF-1096 cream 0.25%, 0.5% and 1% and placebo applied twice daily in the treatment of cutaneous lupus erythematosus lesions

 
3
36
Europe
ASF-1096 Cream 0.25%, ASF-1096 Cream 0.5%, ASF-1096 Cream 1.0%,
Astion Pharma A/S
Patients with Discoid Lupus Erythematosus (DLE) or Subacute Cutaneous Lupus Erythematosus (SCLE) symptoms of the skin can be included in this study. Those patients who have a diagnosis of Systemic Lupus Erythematosus (SLE) with DLE or SCLE lesions of the skin can also be included in the study.
 
 
2006-001062-17: Efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with newly developed discoid lupus erythymatosus (DLE) lesions. A multi centre clinical phase 2, placebo controlled and double blind proof of concept study.

 
2
20
Europe
ASF-1096 cream 0.5%,
Astion Danmark A/S
Male or female patients with a clinical diagnosis of either Discoid Lupus Erythmatosus or Systemic Lupus Erythmatosus and at least one newly developed, sharply demarcated DLE lesion.
 
07/07

Download Options